Abstract: The present disclosure relates to engineering machinery and a dynamic anti-collision method, device, and system for operation space thereof. The dynamic anti-collision method for operation space includes: receiving obstacle information of an obstacle around a boom of engineering machinery and boom motion information of the engineering machinery; determining obstacle coordinates according to the obstacle information and the boom motion information; deciding whether the obstacle coordinates are located in a predetermined early warning area or not; and indicating an execution device to send out collision warning information in case where the obstacle coordinates are located in the predetermined early warning area.

Abstract: Disclosed are a method, apparatus, system and terminal device for measuring the total radiated power of an array antenna, and a non-transitory computer-readable storage medium. The method includes: dividing an array antenna to be measured into N antenna sub-arrays, the N being greater than or equal to 2; determining a sampling interval according to the sizes of the N antenna sub-arrays; determining sampling points according to the sampling interval; and determining the total radiated power of the entire array antenna according to the equivalent isotropic radiated power of the sampling points.

Abstract: Disclosed are a method, apparatus, system and terminal device for measuring the total radiated power of an array antenna, and a non-transitory computer-readable storage medium. The method includes: dividing an array antenna to be measured into N antenna sub-arrays, the N being greater than or equal to 2; determining a sampling interval according to the sizes of the N antenna sub-arrays; determining sampling points according to the sampling interval; and determining the total radiated power of the entire array antenna according to the equivalent isotropic radiated power of the sampling points.

Abstract: Systems and methods for predicting a sensitivity of the cancer to an anti-programed cell death 1 (PD-1) immunotherapy are disclosed. The method can comprise determining a presence of at least one mutation in at least one target gene/protein in a sample of the cancer, wherein the target gene can include a PTEN, a PTPN11, and/or a BRAF gene/protein. If the PTPN11 or BRAF gene/protein includes at least one mutation and/or the PTEN gene/protein is a wild type PTEN gene/protein, then the cancer can be predicted to be sensitive to the PD-1 immunotherapy.